The susceptibility of Helicobacter pylori to the rifamycin, rifaximin.
Forty strains of Helicobacter pylori had an MIC(50) of 4 mg/L of the non-absorbably antibiotic, rifaximin. Neither synergy nor antagonism was demonstrated when the drug was combined with ampicillin, metronidazole and omeprazole and the rate of spontaneous mutation was less than 1 in 10(8). With these in-vitro characteristics, rifaximin should now be assessed for clinical efficacy.
Holton
J
J
Department of Medical Microbiology, University College London Medical School, UK.
Vaira
D
D
Menegatti
M
M
Barbara
L
L
D000667:Ampicillin / Q000494:pharmacology; D004347:Drug Interactions; D004359:Drug Therapy, Combination / Q000494:pharmacology; D016480:Helicobacter pylori / Q000187:drug effects* / Q000235:genetics; D008795:Metronidazole / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D009154:Mutation; D009853:Omeprazole / Q000494:pharmacology; D012294:Rifamycins / Q000494:pharmacology*; D000078262:Rifaximin
D012294:Rifamycins; D008795:Metronidazole; D000667:Ampicillin; D009853:Omeprazole; D000078262:Rifaximin